Traws Pharma Announces Board & Executive Changes
Ticker: TRAW · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $250,000, $150,000, $75,000, $2 billion, $42,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, board-of-directors
TL;DR
Traws Pharma shakes up its board and exec pay - new faces, new plans.
AI Summary
Traws Pharma, Inc. announced on February 5, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans. Specific details regarding the individuals involved and the financial impact of these changes are outlined within the report.
Why It Matters
Changes in a company's leadership and compensation structures can signal shifts in strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's strategic direction and financial stability.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former Company Name
FAQ
What specific roles have been affected by the director and officer changes at Traws Pharma?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', suggesting shifts in key leadership positions.
When did the reported changes in directors and officers take effect?
The earliest event reported is dated February 5, 2025.
What is the primary business of Traws Pharma, Inc. according to the filing?
Traws Pharma, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What is the SEC file number for Traws Pharma, Inc.?
The SEC file number for Traws Pharma, Inc. is 001-36020.
What other information is Traws Pharma, Inc. required to file as part of this 8-K?
In addition to the changes in directors and officers, the filing also includes 'Financial Statements and Exhibits'.
Filing Stats: 1,418 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2025-02-07 16:30:33
Key Financial Figures
- $250,000 — he Company agreed to (i) pay Mr. Guerin $250,000 (less standard deductions and withholdi
- $150,000 — e Termination Date; (ii) pay Mr. Guerin $150,000 (less standard deductions and withholdi
- $75,000 — Termination Date; (iv) grant Mr. Guerin $75,000 of restricted stock units on the Termin
- $2 billion — ife science companies raising more than $2 billion in capital, building finance organizati
- $42,000 — l pay Ms. Brennan total compensation of $42,000 per month for services to be rendered i
- $425,000 — ll provide for an annual base salary of $425,000, the grant of 115,000 restricted stock
Filing Documents
- tm255838d1_8k.htm (8-K) — 33KB
- tm255838d1_ex10-1.htm (EX-10.1) — 74KB
- tm255838d1_ex10-2.htm (EX-10.2) — 15KB
- 0001104659-25-010580.txt ( ) — 321KB
- tmb-20250205.xsd (EX-101.SCH) — 3KB
- tmb-20250205_lab.xml (EX-101.LAB) — 33KB
- tmb-20250205_pre.xml (EX-101.PRE) — 22KB
- tm255838d1_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Separation Agreement and Release of all Claims, by and between Traws Pharma, Inc. and Mark Guerin, dated February 5, 2025. 10.2 Offer Letter, by and between Traws Pharma, Inc. and Nora Brennan, dated February 5, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 7, 2025 TRAWS PHARMA, INC. By: /s/ Werner Cautreels Werner Cautreels Chief Executive Officer